SLC5A2 and chronic kidney disease: Additionally, patients with T2DM and CKD experienced a 29% reduction in adverse CV outcomes, while those with HFpEF showed a 28% risk reduction, underscoring the broad therapeutic efficacy of SGLT2 inhibitors across different CKD stages and comorbid conditions [65].